Genetically Targeted Antifungal Therapeutics: A CRISPR-dCas9--RNAi Hybrid Framework with Dual-Gene Targeting, Evolutionary Escape Modeling, Bayesian Inference, Stochastic Simulations, and In Vitro/In Vivo Validation Protocols

This study delineates a state-of-the-art framework for Genetically Targeted Antifungal Therapeutics (GTAT), fusing CRISPR-dCas9 with RNAi for dual-gene silencing of \textit{ERG11} and \textit{FKS1} in \textit{Candida albicans}. The architecture integrates probabilistic evolutionary escape modeling via Poisson processes, Gillespie stochastic simulations incorporating fitness costs and population bottlenecks, and a hierarchical Bayesian framework for parameter inference on mRNA decay kinetics using numerical ODE solutions for enhanced mathematical precision. Synthetic data illustrate the model, yielding posterior means of bioavailability \(\hat{\phi} = 0.61\) (95\% HDI: [0.52, 0.70]) and silencing efficiency \(\hat{\eta} = 1.15~\mathrm{h}^{-1}\) (95\% HDI: [0.92, 1.38]), predicting 98.7\% knockdown at 12 hours (95\% HDI: [97.2\%, 99.4\%]). Limitations of synthetic data are transparently addressed, with detailed protocols for RT-qPCR in clinical isolates, cytotoxicity in HepG2/HEK293 cells, off-target RNA-seq, and extension to in vivo murine candidiasis models. The model further incorporates nuclease kinetics, macrophage clearance via Michaelis-Menten approximations, TLR-mediated immune modulation by PEGylated chitosan-lipid nanoparticles (CLNPs), and quantitative systems pharmacology (QSP) integration for translational PK/PD predictions. Dual-targeting suppresses escape probability from \(2.4 \times 10^{-3}\) to \(5.8 \times 10^{-6}\), with Gillespie simulations affirming resilience under varying population dynamics and selection pressures. Hypotheses are falsifiable, reproducible, and anchored in fungal genomics, systems pharmacology, evolutionary dynamics, and immunology, positioning GTAT as a paradigm-shifting platform for precision antimicrobials amid escalating resistance, informed by recent advances in CRISPR-Cas fungal applications and RNAi delivery.